Madison Asset Management LLC Has $15.61 Million Position in AbbVie Inc. $ABBV

Madison Asset Management LLC cut its holdings in AbbVie Inc. (NYSE:ABBV) by 4.0% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 67,401 shares of the company’s stock after selling 2,791 shares during the quarter. Madison Asset Management LLC’s holdings in AbbVie were worth $15,606,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Center for Financial Planning Inc. boosted its position in shares of AbbVie by 6.6% in the 3rd quarter. Center for Financial Planning Inc. now owns 18,141 shares of the company’s stock worth $4,200,000 after purchasing an additional 1,116 shares during the last quarter. Nicholson Meyer Capital Management Inc. acquired a new position in AbbVie in the third quarter valued at about $243,000. Stratos Wealth Partners LTD. boosted its holdings in AbbVie by 6.2% during the third quarter. Stratos Wealth Partners LTD. now owns 178,266 shares of the company’s stock worth $41,276,000 after buying an additional 10,346 shares during the last quarter. Stratos Wealth Advisors LLC grew its position in shares of AbbVie by 7.3% during the 3rd quarter. Stratos Wealth Advisors LLC now owns 15,866 shares of the company’s stock worth $3,674,000 after buying an additional 1,073 shares during the period. Finally, Stratos Investment Management LLC increased its stake in shares of AbbVie by 0.9% in the 3rd quarter. Stratos Investment Management LLC now owns 27,153 shares of the company’s stock valued at $6,287,000 after acquiring an additional 243 shares during the last quarter. Institutional investors and hedge funds own 70.23% of the company’s stock.

AbbVie Trading Down 0.8%

Shares of NYSE ABBV opened at $220.74 on Thursday. The company has a fifty day moving average price of $223.47 and a 200 day moving average price of $220.29. The firm has a market cap of $390.12 billion, a PE ratio of 93.53, a PEG ratio of 0.77 and a beta of 0.35. AbbVie Inc. has a 1-year low of $164.39 and a 1-year high of $244.81.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.65 by $0.06. The firm had revenue of $16.62 billion for the quarter, compared to the consensus estimate of $16.39 billion. AbbVie had a negative return on equity of 4,184.47% and a net margin of 6.91%.The company’s revenue for the quarter was up 10.0% on a year-over-year basis. During the same quarter last year, the business posted $2.16 EPS. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Equities research analysts forecast that AbbVie Inc. will post 12.31 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the stock. Citigroup reduced their price objective on shares of AbbVie from $235.00 to $230.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 27th. Weiss Ratings reissued a “hold (c)” rating on shares of AbbVie in a report on Wednesday, January 21st. BMO Capital Markets restated an “outperform” rating and issued a $258.00 price objective on shares of AbbVie in a research report on Thursday, January 15th. UBS Group reduced their target price on AbbVie from $240.00 to $230.00 and set a “neutral” rating on the stock in a report on Thursday, February 5th. Finally, Morgan Stanley boosted their target price on AbbVie from $269.00 to $270.00 and gave the company an “overweight” rating in a research note on Thursday, February 5th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $251.00.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Positive: AbbVie’s real‑world PHASES migraine study could expand uptake for ubrogepant (an oral migraine treatment), improving its competitive positioning in migraine care and incremental revenue potential. AbbVie’s Real-World Migraine Study Could Quietly Boost Ubrogepant’s Market Potential
• Positive Sentiment: Positive: AbbVie updated its Phase 2 elezanumab study in acute cervical spinal cord injury — any favorable signals in neuroscience would bolster the pipeline and longer‑term growth optionality beyond immunology and aesthetics. AbbVie Updates Phase 2 Elezanumab Study in Acute Cervical Spinal Cord Injury: What Investors Should Watch
• Neutral Sentiment: Neutral: Analyst coverage is shifting — some upgrades/notes frame AbbVie as a stronger value/growth combination given Rinvoq and Skyrizi momentum, which supports the longer‑term revenue thesis but may be priced in. How Recent Analyst Shifts Are Reframing AbbVie (ABBV) And Its Valuation Story
• Neutral Sentiment: Neutral: Research/commentary expects 2026 top‑line growth from Rinvoq and Skyrizi (offsetting Humira erosion); these projections support consensus revenue targets but leave sensitivity to execution and pricing. Here’s What Will Drive AbbVie’s Top-line Growth in 2026
• Neutral Sentiment: Neutral: Coverage highlighting AbbVie as a value/attractive income stock (Zacks, Seeking Alpha mentions) can support demand from income‑oriented investors even as valuation debates continue. Here’s Why AbbVie (ABBV) is a Strong Value Stock
• Negative Sentiment: Negative: The big near‑term headwind is CMS selecting Botox for price negotiation under the Inflation Reduction Act; AbbVie filed suit against HHS challenging the move. If price controls are upheld, Botox revenue and pricing could be materially affected; the lawsuit increases regulatory uncertainty and likely pressured shares. AbbVie sues US health agency over Botox price controls
• Negative Sentiment: Negative: Reports that AbbVie is reshaping U.S. operations with Medicaid concessions and broader pricing/alignment moves (including commentary about large domestic manufacturing deals) suggest margin and access tradeoffs; these actions can depress near‑term profitability even if they support market access. AbbVie Reshapes U.S. Operations With Medicaid Concessions And Growth Focus

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.